Resource Logo
PR Newswire

Bioject Signs Agreement With Path to Develop and Evaluate a Disposable- Cartridge Jet Injection System for Global Immunization




 

BEDMINSTER, N.J., July 19 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, announced today that it has signed a collaboration agreement with PATH, an international nonprofit organization whose mission is to improve the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors.

Under terms of the agreement, Bioject will design and develop a needle- free, single-dose cartridge immunization system that will be evaluated by PATH using a combination of performance based bench testing and user focus groups in the developing world. This testing and evaluation will be conducted in order to demonstrate the potential benefit of this technology for the developing world.

"PATH has received support from private foundations for needle-free jet injection devices to be re-introduced into the developing world for immunization," said Jim O'Shea, Chairman, President and CEO of Bioject. "We are pleased that PATH has selected Bioject as a collaborator for this project, and we are looking forward to supporting this public health organization."

About Bioject

Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with operations in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid that penetrates the skin and deposits vaccine in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies. For more information about Bioject, visit http://www.bioject.com.

About PATH

PATH is an international, nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH's work improves global health and wellbeing.

Headquartered in Seattle, Washington, PATH has 19 offices in 13 countries. PATH currently works in more than 100 countries in the areas of reproductive health; vaccines and immunization; HIV/AIDS and tuberculosis; and children's health and nutrition.

For more information about PATH, please visit http://www.path.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the products will not be accepted by the market, uncertainties related to the time required for the Company to complete research and development, obtain necessary clinical data and government clearances, the risk that the Company may be unable to produce our products at a unit cost necessary for the products to be competitive in the market and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject's business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.

SOURCE Bioject Medical Technologies Inc.

Web Site: http://www.bioject.com



 


Copyright © 2004 -PR Newswire, Publisher. All rights reserved to PR Newswire.. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PR Newswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019.

Information in this article was accurate in July 19, 2004. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.